ACT Brief: Funding Gaps and Indication Decisions in Early-Stage Programs, Recruitment Funnel Leak Diagnosis, and Mega-Merger Speculation Denial

This is the Applied Clinical Trials Brief—your fast track to the latest insights shaping clinical operations and drug development.

• In part two of her interview, Stella K. Vnook, CEO of Kaida BioPharma and founder of Aviva Ventures, identified the funding gap and indication selection trade-offs as the most consequential risks facing early-stage programs today. Great assets still fall behind when those early decisions go wrong, and the consequences cascade through all subsequent development planning.
• In a new contributed article, Yuchen Gan examined where the recruitment funnel leaks worst, finding that the biggest loss occurs at the top when patients and trials never meet rather than at the bottom when reached patients decline to participate. Over 56 percent of enrollment shortfall stems from lack of suitable trial availability at where patients receive care, yet most recruitment budgets focus on persuasion optimization and AI-powered screening of already-visible candidates.
• A senior source denied any active discussions between AstraZeneca and Bristol Myers Squibb over a potential 400-billion-dollar combination, stating flatly there was no deal and never was a basis for one. The denial followed three days of market speculation triggered by initial reports, with regulatory risk from US antitrust authorities cited as a likely impediment had talks proceeded.

That's all for today's ACT Brief. Join us tomorrow for more updates shaping clinical operations and drug development. Thanks for listening.